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Background. Minimal change nephrotic syndrome (MCNS)
is a major problem in pediatric nephrology. While the pathogen-
esis of MCNS is not known, the latest discoveries in the genetic
diseases indicate that glomerular epithelial cells (podocytes)
and the slit diaphragm play a primary role in development of
proteinuria. Because nephrin is known to be a major compo-
nent of the slit diaphragm, we analyzed the structure of nephrin
gene (NPHS1) in patients with MCNS of different severity.
Methods. Clinical data and DNA samples were collected from
25 adults who had biopsy-proven MCNS in childhood. A direct
sequencing was performed to all 29 exons of the NPHS1 gene.
The significance of the findings was evaluated by similar analysis
of DNA samples from 25 healthy control patients.
Results. The analysis of NPHS1 revealed no specific MCNS-
associated mutation. However, 5 of the 25 MCNS patients had
heterozygous allelic variants leading to nonconservative amino
acid substitutions not previously reported (G879R; R800C;
T294I; A916S). One of the five patients also had the Fin-major
mutation, and two had new, conservative amino acid substitu-
tions (S786N; A342G). Three of the five patients were classified
as steroid sensitive, one was an early nonresponder, and one
patient showed clear resistance to steroid treatment. Six known
polymorphic changes in NPHS1 were also found, three of them
leading to amino acid changes. The number of allelic variants
was high both in MCNS patients and control patients (mean 3.0
and 2.6).
Conclusion. The results suggest that genetic changes in
nephrin may have a pathogenetic role in some patients with
MCNS.
Minimal change nephrotic syndrome (MCNS) is the
most common form of nephrotic syndrome in childhood.
While most patients respond to steroid treatment, the
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disease is characterized by more or less frequent relapses
[1, 2]. The pathophysiology of MCNS is not known. Glu-
cocorticoids and other immunomodulating drugs induce
remission, suggesting that MCNS has an immunologic ba-
sis. No visible inflammation is present in kidney glomeru-
lus, and it has been postulated that T lymphocytes might
produce a circulating factor that alters the glomerular per-
meability of the glomerular capillary wall [3]. However,
no such factor has been isolated.
It is also unknown which part of the glomerular sieve is
affected in MCNS. The glomerular filter is composed of
three layers: a fenestrated endothelium, the glomerular
basement membrane, and podocyte foot processes con-
nected by the slit diaphragm. Recent data on genetic
diseases clearly indicate that the slit diaphragm is cru-
cial in preventing the leakage of the plasma proteins into
urine [4–6]. Nephrin is a major component of the slit di-
aphragm. It is a transmembrane protein belonging to the
immunoglobulin superfamily containing eight extracel-
lular immunoglobulin (Ig) domains and one fibronectin
motif (Fig. 1). Mutations in the nephrin gene (NPHS1)
are responsible for the congenital nephrotic syndrome
of the Finnish type (CNF, NPHS1), which is character-
ized by heavy proteinuria starting already in utero [7,
8]. The disease is highly enriched in Finland, with a fre-
quency of 1/8200 newborns [9]. NPHS1 consists of 29 ex-
ons and has a size of 26 kb. The Finnish CNF children
have two mutations, Fin-major in exon 2 and Fin-minor
in exon 26, which account for 97% of the cases in Finland
[7]. Both mutations lead to a truncated protein, which is
not expressed on the podocyte surface [10]. In contrast
to this, the non-Finnish patients have “individual” muta-
tions, and more than 60 mutations along NPHS1 have so
far been described [11–13]. In the Finnish CNF patients,
lack of nephrin in the kidney glomerulus leads to absence
of the slit diaphragm, as studied by electron microscopy
[10].
What the role of nephrin and the slit diaphragm is in
MCNS is not known. We recently found that the slit di-
aphragm is often missing in MCNS kidneys, similar to
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Table 1. Characteristics of the MCNS patients
Feature No.
No. of patients 25
Male/female 19/6
Age at onset years 4.9 (0.8–14.5)a
Duration of disease years 6.6 (0.3–27)a
Number of relapses 9.4 (0–28)a
Steroid sensitive/resistant 20/5b
Infrequent/frequent relapses 12/13c
Steroid dependence: no/yes 19/6
Follow-up data
Age years 35.2 (25.8–42.4)a
Proteinuric episodes continue: no/yes 22/3
Renal failure: no/yes 25/0
aMean (range).
bSteroid resistance refers to cases with proteinuric episodes not responding to
prednisolone therapy in four weeks.
cFrequent relapses refer to cases with at least four episodes/year.
that in CNF [14]. Also, altered expression of nephrin
has been reported in MCNS kidneys [15, 16]. Whether
these are primary or secondary changes is not clarified.
Nephrin synthesis in MCNS kidneys has been reported
to be normal in most published studies [17, 18]. How-
ever, one can speculate that qualitative, genetic changes
in nephrin might make the protein functionally or struc-
turally defective, and such a “weak” component would
render the glomerular filter vulnerable to pathogenic pro-
cesses (e.g., an immunologic attack.
This prompted us to study the structure of nephrin gene
in patients with MCNS. The Finnish patients were espe-
cially suitable for this analysis because the Finns are ge-
netically homogenous and have a high frequency of the
two NPHS1 mutations. Because of this founder effect
one might expect to find only a limited number of pos-
sible nucleotide changes predisposing to MCNS. For the
genetic analysis we chose 25 adults who had been treated
for MCNS in childhood, so that any mistake in the di-
agnosis or outcome could be avoided. The sequencing
of all 29 NPHS1 exons did not reveal any homozygous
mutations in MCNS patients. However, heterozygous nu-
cleotide changes were common especially in patients with
severe form of MCNS, suggesting that genetic factors may
play a role in the development and severity of MCNS.
METHODS
Subjects
The study group consisted of 25 adults who had been
treated for MCNS in the Hospital for Children and Ado-
lescence, University of Helsinki, during the period of 1965
to 1980. Clinical data including the medication, number
of relapses, and laboratory values were recorded. The pa-
tients were selected for the NPHS1 analysis because they
all had a biopsy-proven MCNS and a clinical disease of
variable severity. A clinical questionnaire was send to all
patients to clarify the present health status. The patients’
possible signs of renal disease were verified by measuring
serum creatinine, albumin, cholesterol, and hemoglobin
values, and performing urinalysis. Blood samples were
collected for the DNA analyses. A family history was
taken, and absence of nephrotic syndrome in the first-
degree relatives was required.
The clinical data of the 25 patients are presented in
Tables 1 and 3. The severity of the disease varied greatly,
and three patients still had nephrotic periods as adults;
however, none showed any sign of renal failure. For sta-
tistical analyses the patients could be divided in groups
according to the classification of the International Study
Group [1]. Twenty patients were regarded as steroid-
sensitive cases. Nine of them had infrequent relapses, and
11 had frequent relapses (at least four episodes/year). Six
of the patients in the latter group also showed steroid de-
pendence. Steroid resistance was observed in five cases.
It was defined as a failure to achieve response in spite
of four weeks’ therapy with prednisone (60 mg/m2/day).
One of these five was an early nonresponder (patient 21
in Table 3), and two were classified as late nonresponders
(patients 23 and 25). In the latter two cases remission was
achieved with steroids within a week in the first protein-
uric episode. However, later episodes showed variable
responsiveness to both steroids and alkylating agents.
While the duration of the disease was 2.5 years in the first
case, the other patient was still having nephrotic periods
in adulthood. Two patients (patients 22 and 24) had no
clear response to steroid treatment in the initial episode.
Both patients attained remission after a course of cyto-
toxic therapy.
Control patients included 35 young adults with no per-
sonal or family history of kidney diseases. Both study
subjects and control subjects were of the Finnish origin.
Methods
Genomic DNA was isolated according to standard lab-
oratory protocol from frozen or fresh peripheral blood
samples using conventional molecular biology technique
(Puregene EPTM DNA Purification Kit; Gentra Systems,
Minneapolis, MN, USA). The molecular analysis of the
nephrin gene was performed using direct sequencing. Ex-
ons were amplified by polymerase chain reaction (PCR)
with flanking intron primers designed for exons 1 to 29,
and the reactions were performed in total volumes of
25 lL as previously described [11]. Occasionally, the de-
naturation temperature was raised up to 98◦C (exons
12 and 13), or betaine was added to the reaction mix-
ture. PCR products were subjects to automated sequence
analysis by bigdye-terminator reactions (Automated Se-
quencer ABI 377 and Genetic Analyzer 3100; Applied
Biosystems, Foster City, CA, USA). All 29 exons were se-
quenced from the 25 MCN patients. Eleven exons [3, 8, 9,
10, 11, 17–20, 24, 26] showed sequence variants, and were
1858 Lahdenkari et al: Nephrin gene analysis in MCNS
Ala342Gly
(Patient 24)
Arg800Cys
(Patient 21 and 24)
Ser786Asn
(Patient 16)
Thr294Ile
(Patient 10)
Fin-major
(Patient 21)
Ala916Ser
(Patient 14)
Gly879Arg
(Patient 16)
N
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C Fig. 1. Amino acid substitutions in five pa-
tients with minimal change nephrotic syn-
drome (MCNS). The changes were found
in a spacer area between immunoglobulin
(Ig) domain 3 and 4 (A342G), in Ig-7 do-
main (R800C), and in Ig-8 domain (G879R,
A916S). Two changes occur at nonconserved
sites in the Ig-3 (T294I) and Ig-7 (S786N).
analyzed from the 25 control subjects. In addition, the
five exons [8, 9, 18–20] carrying new amino acid changes
were analyzed from 10 additional control subjects so that
the total number of control chromosomes was 70.
Statistical analysis was done by Student t test. The study
was approved by the Ethics Committee of the Hospital
for Children and Adolescents, University of Helsinki. In-
formed consent was obtained from all patients.
RESULTS
Allelic variants of NPHS1
All 29 exons in the NPHS1 gene were directly se-
quenced from the DNA of 25 MCNS patients. No ho-
mozygous mutations were observed in MCNS patients.
While Fin-major mutation in exon 2 was observed in one
patient, none of the patients had Fin-minor mutation in
exon 26. A total of 12 sequence variants were observed in
11 exons, as summarized in Table 2. To examine the sig-
nificance of these changes, the same exons from the DNA
of 25 control subjects were also sequenced (Table 2), and
the results were compared with the published data [11,
12, 19, 20] and public databases (dBSNP, SNPper).
Six of the 12 nucleotide changes were known poly-
morphic variants (SNP) (Table 2). Three of these caused
an amino acid substitution, and three had no effect on
the amino acid sequence of nephrin. Nucleotide changes
were especially common in exons 3 and 26. The num-
ber of variants in the 11 exons tested varied from 1 to
6 (mean 3.0) in MCNS patients, and from 0 to 5 (mean
2.6) in control subjects (P = NS) (Tables 2 and 3). Nine
of the 20 steroid-sensitive MCNS patients had a mild dis-
ease (1–4 relapses), and 11 were frequent relapsers (4–27
episodes). The mean number of nucleotide changes was
2.3 and 3.5 in the two groups, respectively (P < 0.05).
Six of the frequent relapsers were steroid-dependent and
had, on average, 4.2 nucleotide changes compared with
patients with no dependence to steroids (mean 2.4) (P =
0.001). The mean number of amino acid substitutions was
2.0 and 1.4 in the two groups, respectively (P = NS).
MCNS patients with nonconservative amino
acid substitutions
Five MCNS patients had six heterozygous allelic vari-
ants, resulting in amino acid changes of nephrin protein
(Table 2, Fig. 1). Five of the six amino acid changes were
previously unreported.
Patient no. 16 (Table 3) had a nucleotide change of
2635G>A in exon 19, causing a substitution of neu-
tral glycine by positively charged arginine (G879R) at
a conserved site of Ig-8 domain, and a nucleotide change
2357G>A in exon 18, causing a conservative amino acid
substitution of serine by asparagine (S786N) at a noncon-
served site of Ig-7 domain. The patient had 18 proteinuric
episodes in childhood. After 18 years of remission, one
relapse occurred in adulthood. The present kidney func-
tion of the patient is normal (serum creatinine 89 lmol/L).
The mother of this patient carried only the substitution
G879R, suggesting that the two variants in this patient
were in different NPHS1 alleles. As the father of the pa-
tient was deceased, DNA sample was not available for
the analysis.
Patient no. 24 had a 2398C>T change in exon 18, lead-
ing to a substitution of basic arginine by cysteine (R800C)
at a conserved site in the Ig-7 domain, and a 1025C>G
transition in exon 9, causing a conservative amino acid
substitution of alanine by glycine (A342G) at a conserved
site between motifs Ig-3 and Ig-4. This patient responded
poorly to steroid treatment. The duration of the disease
was 5.8 years, and the present kidney function is good
(serum creatinine 86 lmol/L). Both parents of this pa-
tient were deceased, which hampered the analysis of the
allelic variants. The R800C-substitution was found in a
heterozygous form in one of the 35 control subjects.
Patient no. 21 had a Fin-major mutation in exon 2, lead-
ing to a truncated nephrin peptide of only 90 amino acids
and the same nonconservative R800C substitution in Ig-7
domain as patient 24. The initial proteinuric episode at
the age of seven years responded poorly to steroids (early
nonresponder), but the four relapses were successfully
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Table 2. Amino acid substitutions and polymorphisms of the NPHS1 gene in 25 MCNS patients and 25 or 35 control subjects
No. of changes
per alleles
Nucleotide Effect on
Exon change protein MCNS Control subjects Comment
9 1025C→G A342G 1/50 0/70 New conservative amino acid substitution in patient no. 24. Alanine is
substituted by glycine. Both amino acids are neutral and hydrophobic.
Change occurs at conserved site in the area between motifs Ig-3 and Ig-4.
18a 2357G→A S786N 1/50 0/70 New conservative amino acid change (serine→asparagine) in patient no. 16
with continuing nephrotic periods in adulthood. Both amino acids are
neutral and contain nonpolar side chain. Change occurs at nonconserved
site in the Ig-7 domain.
18b 2398C→T R800C 2/50 1/70 New non-conservative amino acid substitution was found in patients no 21
and 24, who did not respond to steroid treatment. Hydrophilic and basic
arginine is substituted by neutral cysteine containing reactive sulfhydryl
group. Change occurs at conserved site in the Ig-7 domain.
19 2635G→A G879R 1/50 0/70 New nonconservative amino acid substitution in patient no. 16 with
continuing nephrotic periods in adulthood. Neutral glycine with nonpolar
side chain is substituted by positively charged arginine. Change occurs at
conserved site in the Ig-8 domain.
20 2746G→T A916S 1/50 0/70 New nonconservative amino acid substitution in patient no. 14. Hydrophobic
alanine with nonpolar side chain is converted to hydrophilic serine with
polar side chain. Change occurs at conserved site in the Ig-8 domain.
8 881C→T T294I 1/50 0/70 Nonconservative amino acid change from hydrophilic threonine to neutral
isoleucine in patient no. 10. Previously found also in a mother of a CNF
child, Beltcheva et al, 2001. Change occurs at a site in the Ig-3 domain,
which is not conserved during evolution.
3 349 G→A E117K 24/50 20/50 Known polymorphism. Amino acid change: glutamic acid→lysine (Lenkkeri
et al, 1999).
10 1223G→A R408Q 4/50 3/50 Known polymorphism. Amino acid change: arginine→glutamine (Lenkkeri
et al, 1999).
24 3230A→G N1077S 3/50 9/50 Known polymorphism. Amino acid change: asparagine→serine (Lenkkeri
et al, 1999).
11 1320C→T P440P 2/50 4/50 New polymorphism. No amino acid change.
17 2289C→T V763V 2/50 4/50 New polymorphism. No amino acid change.
26 3315G→A S1105S 32/50 24/50 Known polymorphism. No amino acid change (Beltcheva et al, 2001).
The number of nucleotide changes per 50 or 70 alleles. The patient number refers to Table 3.
treated with prednisone. The duration of the disease was
5.1 years. The patient is now 40 years old and is doing
clinically well, with a slightly elevated serum creatinine
value (126 lmol/L). The analysis of DNA sample from the
mother of this patient revealed that he carried only the
nucleotide change R800C, suggesting that the two vari-
ants in the patient were in different alleles. Because the
father of this patient was deceased and no DNA sample
was available, a de novo mutation (Fin-major) cannot to-
tally be excluded. However, based on the experience on
the CNF families, a sporadic Fin-major mutation in this
patient seems very unlikely.
Patient no. 10 had a nucleotide change of 881C>T in
exon 8, causing a substitution of hydrophilic threonine by
neutral isoleucine (T294I) at a nonconserved site in Ig-3
domain, and a nucleotide change of 3230A>G in exon
24, leading to a known polymorphic amino acid substitu-
tion of asparagine by serine (N1077S) in transmembrane
part of nephrin polypeptide. Interestingly, this patient had
transient proteinuria in infancy before MCNS started at
the age of 5 years (Table 3). The T294I substitution has
previously been reported in a mother of a CNF child and
has been regarded as a polymorphic change [12].
Patient no. 14 had a single change of 2746G-T in exon
20, resulting in a substitution of hydrophobic alanine by
hydrophilic serine (A916S) at a conserved site in Ig-8
domain. The patient had 13 relapses in childhood and is
now clinically well (Table 3).
DISCUSSION
In this work we studied the possible role of the ma-
jor slit diaphragm protein, nephrin, in the pathogenesis
of MCNS by analyzing the nephrin gene (NPHS1) struc-
ture in patients with a biopsy-proven MCNS in childhood.
While the analysis did not reveal any specific MCNS-
associated mutation, five of the 25 patients had het-
erozygous amino acid substitutions, probably leading to
unfavorable conformational changes in nephrin struc-
ture. This suggests that genetic defects in glomerular
filter proteins may play a role in some patients with
MCNS.
Despite careful work in many laboratories, the patho-
genesis of MCNS has remained a mystery for decades.
While it is believed that the disease has an immunologic
basis, no antibody or T-cell–mediated process has been
detected in the MCNS kidneys [3, 21]. Alterations in
1860 Lahdenkari et al: Nephrin gene analysis in MCNS
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the T-lymphocyte subpopulations in the peripheral blood
during relapses have been reported. Also, changes in the
cytokine production have been found in MCNS patients
[22]. As is the case with focal segmental glomeruloscle-
rosis (FSGS), the production of a soluble “proteinuric
factor” has been suggested. This factor would penetrate
into the glomerular capillary wall and interfere with the
filtration barrier.
What goes wrong in the glomerular filter in MCNS is
not known. Structural changes in the GBM, such as a
decrease in anionic proteoglycans, have been suggested
[23]. In animal models, detachment of podocyte foot pro-
cesses from the GBM have correlated with the onset
of proteinuria, suggesting that areas of denuded GBM
might serve as the sites of protein leakage [24]. The lat-
est discoveries in the genetic diseases, however, indicate
that podocytes and the slit diaphragm are crucial for
glomerular ultrafiltration [4–6]. Defects in podocyte pro-
teins, such as nephrin, Neph1, podocin, CD2-associated
protein (CD2AP), and alpha-actinin-4, all cause heavy
proteinuria [25–28]. Thus, a defective podocyte filtration
slit is a probable route for protein leakage.
Nephrin is an important component of the glomerular
filter. Absence of nephrin leads to a distortion of the slit
diaphragm, which can be seen in the Finnish CNF pa-
tients, who have no slit diaphragm filaments in the elec-
tron microscopy [10]. A similar phenomenon was recently
seen also in MCNS kidneys [14]. Also, altered expression
of nephrin, as studied by light and electron microscopy,
has been reported in MCNS [15, 16, 29]. Based on these
data we hypothesized that MCNS patients might have
a genetically vulnerable glomerular filter. Because of its
central role, a defective nephrin would easily predispose
to proteinuria.
Our analysis revealed considerable frequency of allelic
NPHS1 variants in the 100 chromosomes from MCNS
patients and control subjects. A total of 12 nucleotide
changes were observed in 11 exons. Six of the 12 nu-
cleotide changes were known polymorphisms (SNP).
Three of these caused an amino acid substitution, and
three had no effect on the amino acid sequence of
nephrin. Previously, eight exonic SNPs and about 40 in-
tronic SNPs have been registered in public databases
(dBSNP and SNPper). Five of the exonic SNPs (E117K,
P440P, V763V, N1077S, S1105S) were found also in our
patients. Three reported polymorphisms (T741T, S440S,
and I98I) were not found either in our patients or in the
control subjects. The average number of sequence vari-
ants was not significantly higher in MCNS patients com-
pared with control subjects (3.0 vs. 2.6). Within MCNS,
there was a tendency for a higher number of variants
in patients with a complicated disease (steroid depen-
dency) as compared with those with a mild disease (4.2
and 2.4 variants, respectively). Because this difference
was mainly based on nucleotide changes not affecting
nephrin structure, the significance of the finding remains
open.
The frequency of heterozygous Fin-major and Fin-
minor carriers in the Finnish population is high (about
2%), and it was interesting to see whether the carrier-
ship would predispose to MCNS [30]. This was not the
case, because only one of the 25 MCNS patients had het-
erozygous Fin-major mutation. Heterozygous carriers of
Fin-major or Fin-minor have only one functional allele,
which is normally enough (e.g., parents of the CNF chil-
dren do not have proteinuria and can be used as donors
in kidney transplantation). However, during the fetal pe-
riod, NPHS1 mutation carriers have temporary protein-
uria, indicating the necessity of both alleles for sufficient
synthesis of nephrin during glomerulogenesis [31]. Thus,
it seems that after glomerulogenesis is finished, one nor-
mal allele is enough even in a “stress condition” such as
MCNS.
One MCNS patient in this analysis had the Fin-major
mutation in one NPHS1 allele, and a 2398C>T nucleotide
change in the other, causing a substitution of arginine by
cysteine in Ig-7 domain of nephrin (R800C). MCNS man-
ifested in this patient at the age of 7 years and lasted for
5 years. It is interesting that six Finnish CNF patients had
a similar situation, with the Fin-major mutation in one
allele and a missense mutation in the other. Five of them
have received kidney transplantation. However, one pa-
tient has the substitution of arginine by cysteine in the
spacer area close to Ig7-motif (R743C). The patient had
full-blown nephrotic syndrome immediately after birth,
but responded to the anti-proteinuric therapy with in-
domethacin and ACE-inhibitor and, as yet, is the only
Finnish CNF patient (at the age of 5 years) who has not
needed kidney transplantation [10]. Thus, the Finnish pa-
tients with compound Fin-major and missense changes
show a graded severity of disease from CNF to MCNS.
This variation may be explained by the type of the amino
acid substitution that takes place in the nephrin polypep-
tide. Liu et al [32] have shown that most missense mu-
tations associated with typical CNF lead to a defective
folding of the synthesized nephrin, so that the molecule
never reaches the podocyte surface. A less severe change
(as was the case with the R743C substitution) would
lead to a nephrin molecule that is expressed at the slit
diaphragm but is functionally defective and may cause
“atypical” phenotype. We analyzed 35 healthy control
subjects, and the R800C substitution was found in a het-
erozygous form in only one of them. Both of our patients
carrying R800C (patients 21 and 24) also had another de-
fect in their nephrin gene. Therefore, R800C is most likely
a pathogenic alteration and affected the phenotype of pa-
tient 21, who had Fin-major mutation in the other allele.
Four additional MCNS patients had heterozygous, non-
conservative amino acid substitutions in nephrin (G879R;
R800C; T294I; A916S). Three of these were at conserved
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sites in the Ig-domains based on the comparison of hu-
man, rat, and mouse sequences. Two of the patients
also had additional conservative amino acid substitutions
(S786N; A342G). The variants were not found in public
databases dBSNP or SNPper, suggesting that they are
not common polymorphic alterations. The pathogenic
role of the amino acid substitutions remains to be ver-
ified, but it seems possible that they have a dominant-
negative effect on the slit diaphragm architecture. The
situation would then be analogous to that of the other
glomerular filter, the GBM, where heterozygous muta-
tions in type IV collagen alpha 3 and 4 genes (COL4A3,
COL4A4) can have a dominant-negative effect on the
collagen network and the GBM structure, resulting
in a continuous spectrum of phenotypes from classic
Alport syndrome to benign familial hematuria [33, 34].
Nephrin interacts with other slit diaphragm components,
such as Neph1, podocin, and CD2AP, and also takes part
in cell signaling [25, 27, 35–37]. It seems possible that
amino acid changes in critical points of the protein would
interfere with these functions. The change of arginine by
cysteine (R800C) in Ig-7 domain probably causes for-
mation of incorrect disulfide bonds, but otherwise, the
impact of each amino acid substitution on the protein
structure cannot, so far, be predicted because the crys-
tal molecular structure of nephrin is not yet known. It is,
however, interesting that four of the amino acid substi-
tutions in our MCNS patients occurred in Ig-7 and Ig-8
domains, which show clustering of mutations also in CNF
patients [12, 13].
Nephrin is not the only slit diaphragm component, and
it is clear that genetic variation in other podocyte pro-
teins, such as podocin, NEPH1, CD2AP, and a-actinin-4
may equally affect the filter function. Podocin is espe-
cially interesting in this respect. Mutations in podocin
gene (NPHS2) cause the autosomal-recessive form of
FSGS, as well as some of the “sporadic” FSGS cases [26,
38, 39]. Some adult patients with FSGS have been found
to bear a heterozygous mutation (R229Q) that enhances
susceptibility to FSGS in association with a second mu-
tant NPHS2 allele [40]. Interestingly, podocin with the
R229Q amino acid change bound poorly to nephrin, un-
derscoring the importance of the interplay with these
two proteins. Furthermore, Kim et al [41] found recently
that mice that had CD2AP haploinsufficiency showed in-
creased susceptibility to glomerular injury by nephrotoxic
antibodies and immune complexes. They also identified
two human patients who were heterozygous for CD2AP
mutations and still had proteinuria, implicating CD2AP
as a determinant of susceptibility to a glomerular dis-
ease. It is also possible that mutations in two or more
genes are needed to make the glomerular filter suscep-
tible to a pathogenic process. The collaborative effect of
the NPHS1 and NPHS2 genes has already been shown.
Koziel et al reported an overlap in the NPHS1/NPHS2
mutations, and characterized a di-genic inheritance, re-
sulting in a “tri allelic” hit, which converted the pheno-
type from CNF to the congenital form of FSGS [13].
CONCLUSION
MCNS is thought to be a multifactorial disease, and the
basic mechanisms behind MCNS still wait to be solved.
The results here, however, suggest for the first time that
genetic variants of a glomerular filter protein may play a
role in MCNS. Expanding the genetic work to the other
podocyte proteins therefore seems indicated.
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